TAK - Takeda Pharmaceutical Co - ADR
Close
14.89
-0.060 -0.403%
Share volume: 1,859,532
Last Updated: Fri 30 Aug 2024 10:00:03 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$14.95
-0.06
-0.40%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | |
| Report Date | 2022-11-04 | 2023-02-07 | 2023-06-28 | 2023-07-27 | 2023-10-30 | 2024-02-01 | 2024-06-26 | 2024-07-31 | |
| Assets | |||||||||
| Total Assets | 100.895 B | 102.999 B | 105.139 B | 102.226 B | 99.561 B | 100.854 B | 99.830 B | 100.865 B | |
| Current Assets | 18.988 B | 19.799 B | 18.063 B | 17.083 B | 16.482 B | 17.223 B | 16.906 B | 19.315 B | |
| Inventories | 6.594 B | 7.072 B | 7.431 B | 7.487 B | 7.738 B | 8.294 B | 7.994 B | 7.936 B | |
| Other Current Assets | 1.297 B | 1.497 B | 1.364 B | 1.604 B | 1.299 B | 1.478 B | 1.216 B | 1.556 B | |
| Short Term Investments | 1.297 B | 1.497 B | 1.364 B | 1.604 B | 1.299 B | 1.478 B | 1.216 B | 1.556 B | |
| Total Receivables | 5.536 B | 5.948 B | 5.135 B | 5.705 B | 5.276 B | 5.269 B | 4.609 B | 4.801 B | |
| Current Cash | 5.520 B | 5.225 B | 4.019 B | 2.186 B | 2.129 B | 2.045 B | 3.025 B | 4.999 B | |
| Total Non-current Assets | 81.906 B | 83.200 B | 87.076 B | 85.143 B | 83.078 B | 83.631 B | 82.925 B | 81.550 B | |
| Property Plant Equipment | 12.174 B | 12.633 B | 12.740 B | 12.407 B | 12.680 B | 13.058 B | 13.147 B | 12.962 B | |
| Other Assets | 2.833 B | 2.607 B | 2.584 B | 2.441 B | 2.497 B | 2.300 B | 2.590 B | 2.894 B | |
| Intangible Assets | 28.957 B | 28.721 B | 32.162 B | 31.195 B | 29.472 B | 29.052 B | 28.245 B | 27.138 B | |
| Goodwill | 34.542 B | 35.777 B | 36.087 B | 35.811 B | 35.488 B | 36.244 B | 35.747 B | 35.639 B | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 100.895 B | 102.999 B | 105.139 B | 102.226 B | 99.561 B | 100.854 B | 99.830 B | 100.865 B | |
| Total liabilities | 54.469 B | 55.895 B | 57.276 B | 54.398 B | 52.228 B | 53.047 B | 51.773 B | 52.393 B | |
| Total current liabilities | 16.541 B | 17.060 B | 18.696 B | 17.288 B | 15.850 B | 16.183 B | 15.284 B | 15.323 B | |
| Accounts Payable | 2.688 B | 2.907 B | 4.890 B | 3.047 B | 2.819 B | 3.430 B | 3.618 B | 2.914 B | |
| Other liabilities | 2.083 B | 2.168 B | 2.060 B | 1.894 B | 1.508 B | 1.625 B | 1.609 B | 1.548 B | |
| Current long term debt | 4.712 B | 4.215 B | 3.956 B | 5.050 B | 3.899 B | 4.385 B | 3.374 B | 4.371 B | |
| Long term debt | 32.621 B | 33.699 B | 34.477 B | 33.349 B | 33.334 B | 34.292 B | 34.123 B | 35.172 B | |
| Other liabilities | 2.083 B | 2.168 B | 2.060 B | 1.894 B | 1.508 B | 1.625 B | 1.609 B | 1.548 B | |
| Minority interest | 3.873 M | 3.966 M | 4.135 M | 4.264 M | 4.505 M | 4.772 M | 4.896 M | 5.066 M | |
| Total Shareholder equity | 46.426 B | 47.104 B | 47.864 B | 47.828 B | 47.333 B | 47.807 B | 48.058 B | 48.472 B | |
| Common stock | 3.105 B | 3.130 B | 3.088 B | 3.109 B | 3.131 B | 3.143 B | 3.133 B | 3.138 B | |
| Retained earnings | 10.583 B | 11.499 B | 11.609 B | 10.297 B | 9.680 B | 9.905 B | 9.192 B | 8.318 B |